- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02440789
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy
Study Overview
Detailed Description
The study was conducted with an initial lead-in period of 12 weeks where participants remained on ART, without study intervention. Samples were collected to define the pre-intervention steady-state of HIV, inflammation and immune activation parameters.
At week 12, sirolimus therapy was initiated for the planned 20 weeks of treatment. In order to achieve therapeutic levels, sirolimus therapy was initiated with lead-in dose of 0.025 or 0.05 mg/kg/day, depending on the ART regimen. Doses for each participant were then adjusted, based on trough blood sirolimus concentrations, to achieve target concentrations between 5 and 10 ng/mL. There were frequent initial visits for sirolimus trough concentration monitoring and potential dose adjustments, at weeks 12.5, 13, 13.5, 14, 14.5, 15, 15.5 and 16. Then visits occurred at weeks 18, 20, 24, 28 and 32. After the week 32 visit, the planned end of study treatment, there was an additional 12 weeks of post-sirolimus follow-up, with a final visit at week 44.
Study visits included physical examinations, clinical assessments, safety monitoring, and blood and oral swab collection. Anal swabs were collected at week 12 and 32. Samples were stored for subsequent protocol testing for the study outcomes.
In the primary analysis, the significance level was 0.05 for all analyses.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94110
- 801 University of California, San Francisco HIV/AIDS CRS
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20005
- Whitman Walker Health CRS (31791)
-
-
Florida
-
Miami, Florida, United States, 33136
- Univ. of Miami AIDS CRS (901)
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- The Ponce de Leon Center CRS (5802)
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University CRS (2101)
-
-
New York
-
New York, New York, United States, 10011
- Weill Cornell Uptown CRS (7803)
-
Rochester, New York, United States, 14642
- 31787 University of Rochester Adult HIV Therapeutic Strategies Network CRS
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- Univ. of Cincinnati CRS (2401)
-
-
Texas
-
Houston, Texas, United States, 77030
- Houston AIDS Research Team CRS (31473)
-
-
Washington
-
Seattle, Washington, United States, 98104
- University of Washington AIDS CRS (1401)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- HIV-1 infection
- On continuous ART for ≥24 months prior to study entry.
- CD4+ cell count ≥350 cells/mm^3
- Plasma HIV-1 RNA below the level of quantification for ≥24 months.
- White blood cell (WBC) ≥3000/mm^3
- Platelet count ≥125,000/mm^3
- Absolute neutrophil count (ANC) >1300/mm^3
- Aspartate aminotransferase (AST) <1.25 x upper limit of normal (ULN)
- Alanine aminotransferase (ALT) <1.25 x ULN
- Calculated creatinine clearance (CrCl) ≥60 mL/min
- Fasting or non-fasting triglyceride level ≤350 mg/dL
- Fasting or non-fasting LDL <160 mg/dL
- Urine protein to urine creatinine ratio ≤1 g/g from random urine collection
Exclusion Criteria:
- Serious illness requiring systemic treatment and/or hospitalization
- Documentation of any CDC Category C AIDS-indicator condition or oropharyngeal candidiasis (thrush)
- Intended modification of ART during the study.
- Latent tuberculosis (TB) infection
- TB disease within 48 weeks prior to study entry requiring treatment.
- History of active hepatitis B (HBV) infection.
- Hepatitis C virus (HCV) RNA-positive
- Previous myelodysplasia syndrome, lymphoproliferative disease, lung disease, malignancies, congestive heart failure, life-threatening fungal infection or herpes-zoster/varicella-zoster viral infection requiring treatment.
- Detectable Epstein-Barr virus (EBV) in blood
- Active infection other than HIV that required receipt of systemic antibiotic therapy by intravenous infusion
- History of major hypersensitivity reaction to macrolide drugs including angioedema, anaphylaxis, drug-induced dermatitis, or hypersensitivity vasculitis.
- Currently pregnant or breastfeeding, or planning to become pregnant prior to or during the study.
- Use of immunomodulators (eg, interleukins, interferons, and cyclosporine), HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy.
- Active drug or alcohol use or dependence
- Vaccination within 14 days prior to study entry.
- On or planned to change to a PI-based ART or cobicistat-boosted regimen
- Anti-human papillomavirus (HPV) therapies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sirolimus
|
Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks. Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Met the Study-defined Composite Safety Endpoint
Time Frame: Screening to study week 32 (week 20 of Sirolimus)
|
The study-defined primary safety endpoint was a composite endpoint.
A participant was considered to have met the endpoint if the participant 1) experienced a new Grade ≥3 Adverse Event (AE), including signs/symptoms, lab toxicity or clinical event, that was definitely, probably or possibly related to study treatment, as judged by the core team, or 2) had a change in CD4+ cell count ( confirmed >50% decline or to <300 cells/mm3) while on sirolimus.
The screening visit occurred within 60 days of study entry.
|
Screening to study week 32 (week 20 of Sirolimus)
|
Efficacy - Immunologic: Frequency of HIV-1 Gag-specific CD8+ T-cells by Intracellular Staining for IFN-gamma
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Frequency of HIV-1 Gag-specific CD8+ T-cells by intracellular staining for IFN-gamma.
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Efficacy - Immunologic: Change in HIV-1 Gag-specific CD8+ T-cells by Intracellular Staining for IFN-gamma
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Change in HIV-1 Gag-specific CD8+ T-cells by intracellular staining for IFN-gamma (week 32 measurement minus baseline measurement)
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Efficacy - Virologic: CD4+ T-cell-associated HIV-1 RNA
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
CD4+ T-cell-associated HIV-1 RNA.
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Efficacy - Virologic: Change in CD4+ T-cell-associated HIV-1 RNA
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Change in CD4+ T-cell-associated HIV-1 RNA (week 32 measurement minus baseline measurement)
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Efficacy - Virologic: Plasma HIV-1 RNA by SCA
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Plasma HIV-1 RNA by SCA
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Efficacy - Virologic: Change in Plasma HIV-1 RNA by SCA
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Change in plasma HIV-1 RNA by SCA (week 32 measurement minus baseline measurement). Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12). |
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of CD4+ T-cell Counts
Time Frame: At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
CD4+ T-cell counts.
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).
|
At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Change in CD4+ T-cell Counts
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Change in CD4+ T-cell counts (week 32 measurement minus baseline measurement)
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Measurement of HIV-1 RNA Levels
Time Frame: weeks 0, 12, (pre-Sirolimus) 16, 24, 32 (4, 12, 20 weeks on Sirolimus) and 44
|
HIV-1 RNA levels by conventional assay
|
weeks 0, 12, (pre-Sirolimus) 16, 24, 32 (4, 12, 20 weeks on Sirolimus) and 44
|
Cell-associated HIV-1 DNA Levels in Total CD4+ Cells
Time Frame: At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
HIV-1 DNA levels in CD4+ T-cells.
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).
|
At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Change in Cell-associated HIV-1 DNA Levels in Total CD4+ Cells
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Change in HIV-1 DNA levels in CD4+ T-cells (week 32 measurement minus baseline measurement)
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Measurement of HIV-1 Gag-specific CD107a+ CD8+ T-cell Responses
Time Frame: At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Frequency of HIV-1 Gag-specific CD107a+ CD8+ T-cells.
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).
|
At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Change in HIV-1 Gag-specific CD107a+ CD8+ T-cell Responses
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Change in frequency of HIV-1 Gag-specific CD107a+ CD8+ T-cells (week 32 measurement minus baseline measurement)
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Measurement of HIV-1 Gag-specific CD40L+ CD8+ T-cell Responses
Time Frame: At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Frequency of HIV-1 Gag-specific CD40L+ CD8+ T-cells.
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).
|
At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Change in HIV-1 Gag-specific CD40L+ CD8+ T-cell Responses
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Change in frequency of HIV-1 Gag-specific CD40L+ CD8+ T-cells (week 32 measurement minus baseline measurement)
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Measurement of HIV-1 Gag-specific IL-2+ CD8+ T-cell Responses
Time Frame: At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Frequency of HIV-1 Gag-specific IL-2+ CD8+ T-cells.
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).
|
At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Change in HIV-1 Gag-specific IL-2+ CD8+ T-cell Responses
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Change in frequency of HIV-1 Gag-specific IL-2+ CD8+ T-cells (week 32 measurement minus baseline measurement)
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Measurement of HIV-1 Gag-specific MIP1B+ CD8+ T-cell Responses
Time Frame: At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Frequency of HIV-1 Gag-specific MIP1B+ CD8+ T-cells.
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).
|
At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Change in HIV-1 Gag-specific MIP1B+ CD8+ T-cell Responses
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Change in frequency of HIV-1 Gag-specific MIP1B+ CD8+ T-cells (week 32 measurement minus baseline measurement)
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Measurement of HIV-1 Gag-specific TNF-alpha+ CD8+ T-cell Responses
Time Frame: At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Frequency of HIV-1 Gag-specific TNF-alpha+ CD8+ T-cells.
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).
|
At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Change in HIV-1 Gag-specific TNF-alpha+ CD8+ T-cell Responses
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Change in frequency of HIV-1 Gag-specific TNF-alpha+ CD8+ T-cells (week 32 measurement minus baseline measurement)
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Measurement of HIV-1 Gag-specific CD4+ T-cell by Intracellular Staining for IFN-gamma Responses
Time Frame: At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Frequency of HIV-1 Gag-specific CD4+ T-cells by intracellular staining for IFN-gamma.
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).
|
At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Change in HIV-1 Gag-specific CD4+ T-cell by Intracellular Staining for IFN-gamma Responses
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Change in HIV-1 Gag-specific CD4+ T-cells by intracellular staining for IFN-gamma (week 32 measurement minus baseline measurement)
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Measurement of HIV-1 Gag-specific CD107a+ CD4+ T-cell Responses
Time Frame: At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Frequency of HIV-1 Gag-specific CD107a+ CD4+ T-cells.
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).
|
At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Change in HIV-1 Gag-specific CD107a+ CD4+ T-cell Responses
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Change in frequency of HIV-1 Gag-specific CD107a+ CD4+ T-cells (week 32 measurement minus baseline measurement)
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Measurement of HIV-1 Gag-specific CD40L+ CD4+ T-cell Responses
Time Frame: At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Frequency of HIV-1 Gag-specific CD40L+ CD4+ T-cells.
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).
|
At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Change in HIV-1 Gag-specific CD40L+ CD4+ T-cell Responses
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Change in frequency of HIV-1 Gag-specific CD40L+ CD4+ T-cells (week 32 measurement minus baseline measurement).
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Measurement of HIV-1 Gag-specific IL-2+ CD4+ T-cell Responses
Time Frame: At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Frequency of HIV-1 Gag-specific IL-2+ CD4+ T-cells.
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).
|
At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Change in HIV-1 Gag-specific IL-2+ CD4+ T-cell Responses
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Change in frequency of HIV-1 Gag-specific IL-2+ CD4+ T-cells (week 32 measurement minus baseline measurement)
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Measurement of HIV-1 Gag-specific MIP1B+ CD4+ T-cell Responses
Time Frame: At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Frequency of HIV-1 Gag-specific MIP1B+ CD4+ T-cells.
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).
|
At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Change in HIV-1 Gag-specific MIP1B+ CD4+ T-cell Responses
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Change in frequency of HIV-1 Gag-specific MIP1B+ CD4+ T-cells (week 32 measurement minus baseline measurement).
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Measurement of HIV-1 Gag-specific TNF-alpha+ CD4+ T-cell Responses
Time Frame: At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Frequency of HIV-1 Gag-specific TNF-alpha+ CD4+ T-cells.
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).
|
At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Change in HIV-1 Gag-specific TNF-alpha+ CD4+ T-cell Responses
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Change in frequency of HIV-1 Gag-specific TNF-alpha+ CD4+ T-cells (week 32 measurement minus baseline measurement).
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Measurement of %CD69+ CD4+ T-cells
Time Frame: At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Measurement of %CD69+ CD4+ T-cells.
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).
|
At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Change in of %CD69+ CD4+ T-cells
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Change in of %CD69+ CD4+ T-cells (week 32 measurement minus baseline measurement).
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Measurement of %CD69+ CD8+ T-cells
Time Frame: At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Measurement of %CD69+ CD8+ T-cells.
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).
|
At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Change in of %CD69+ CD8+ T-cells
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Change in of %CD69+ CD8+ T-cells (week 32 measurement minus baseline measurement)
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Measurement of %Ki67+ CD4+ T-cells
Time Frame: At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Measurement of %Ki67+ CD4+ T-cells.
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).
|
At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Change in of %Ki67+ CD4+ T-cells
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Change in of %Ki67+ CD4+ T-cells (week 32 measurement minus baseline measurement).
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Measurement of %Ki67+ CD8+ T-cells
Time Frame: At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Measurement of %Ki67+ CD8+ T-cells.
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).
|
At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Change in of %Ki67+ CD8+ T-cells
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Change in of %Ki67+ CD8+ T-cells (week 32 measurement minus baseline measurement)
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Measurement of %PD1+ CD4+ T-cells
Time Frame: At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Measurement of %PD1+ CD4+ T-cells.
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).
|
At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Change in of %PD1+ CD4+ T-cells
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Change in of %PD1+ CD4+ T-cells (week 32 measurement minus baseline measurement)
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Measurement of %PD1+ CD8+ T-cells
Time Frame: At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Measurement of %PD1+ CD8+ T-cells.
Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).
|
At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
|
Change in of %PD1+ CD8+ T-cells
Time Frame: At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Change in of %PD1+ CD8+ T-cells (week 32 measurement minus baseline measurement)
|
At study weeks 0, 12 and 32 (week 20 on Sirolimus)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Timothy Henrich, MD, University of California, San Francisco
- Study Chair: Priscilla Hsue, MD, University of California, San Francisco
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACTG A5337
- 2UM1AI068636 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV-1 Infection
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Helios SaludViiV HealthcareUnknownHiv | HIV-1-infectionArgentina
-
Frontier Biotechnologies Inc.RecruitingHIV-1-infectionUnited States
-
University of ZurichActive, not recruitingHIV-1-infectionSwitzerland
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1-infectionUnited States
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Aelix TherapeuticsCompleted
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1 InfectionUnited States
-
Taipei Veterans General Hospital, TaiwanCompleted
-
Shanghai Public Health Clinical CenterUnknown
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Completed
Clinical Trials on Sirolimus
-
Aadi Bioscience, Inc.Approved for marketingTSC1 | TSC2 | PEComa, Malignant | mTOR Pathway Abberation
-
Johns Hopkins UniversityMacuSight, Inc.CompletedPanuveitis | Uveitis | Posterior Uveitis | Intermediate UveitisUnited States
-
Stefan Schieke MDWithdrawnCutaneous T-cell Lymphoma (CTCL)United States
-
Aadi Bioscience, Inc.CompletedHigh Grade Recurrent Glioma and Newly Diagnosed GlioblastomaUnited States
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)CompletedLymphangioleiomyomatosisUnited States
-
The University of Texas Health Science Center,...Society for Pediatric DermatologyCompletedTuberous Sclerosis | Neurofibromatoses | Neurofibroma | AngiofibromaUnited States
-
Xijing HospitalAir Force Military Medical University, China; Shanghai MicroPort Medical (Group)... and other collaboratorsUnknown
-
Shanghai Jiao Tong University School of MedicineUnknownCoronary Artery DiseaseChina
-
Meril Life Sciences Pvt. Ltd.Lifecare Institute of Medical Sciences and Research Ahmedabad Gujarat IndiaCompleted
-
Paul S Teirstein, MDCordis CorporationCompletedCoronary Artery Disease | Coronary Thrombosis | Coronary RestenosisUnited States